Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma

Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Irimia, Ruxandra, Barbu, Sinziana, Popa, Codruta, Badelita, Sorina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048708/
https://www.ncbi.nlm.nih.gov/pubmed/36975736
http://dx.doi.org/10.3390/hematolrep15010023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048708/
https://www.ncbi.nlm.nih.gov/pubmed/36975736
http://dx.doi.org/10.3390/hematolrep15010023

Ejemplares similares